Novavax, Siegfried extend COVID-19 vaccine production deal

Sep. 28, 2022 12:59 PM ETNovavax, Inc. (NVAX)SGFEFBy: Dulan Lokuwithana, SA News Editor4 Comments

Germany Begins Novavax Covid Vaccinations

Carsten Koall/Getty Images News

  • Swiss life sciences company Siegfried Holding AG (OTC:SGFEF) announced Wednesday that it decided to extend the collaboration with Novavax (NASDAQ:NVAX) for the fill & finish process of the U.S. biotech's COVID-19 vaccine.
  • Accordingly, the initial agreement, expected to expire in 2022, will continue until the end of 2023, with production at Siegfried's (OTC:SGFEF) manufacturing site in Hameln, Germany.
  • The contract manufacturer reiterated its 2022 guidance and mid-term outlook even as a separate deal with German COVID-19 vaccine maker BioNTech (BNTX) ends at the end of the year.
  • The announcement comes after Novavax (NVAX) said Tuesday that 1M doses of its protein-based shot were now available in the U.K.
  • A study based on self-reported COVID test results indicated that case numbers jumped 30% in England over the past week after a downward trend,
  • "We continue to believe in the importance of a diversified national vaccine portfolio to reduce winter pressures on the health service," Novavax (NVAX) Chief Executive Stanley Erck remarked.

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.